Takeuchi I, Kaburaki Y, Arai K, et al. - Researchers examined the efficacy and safety of infliximab for very early-onset inflammatory bowel disease (VEO-IBD). From a Japanese tertiary children's hospital, they identified 17 VEO-IBD patients [five ulcerative colitis type (UCT), five non-UCT with perianal disease (NUC-PD), and seven non-UCT without perianal disease (NUC-NPD)] who had received infliximab as their first biologic. Outcomes support the utility of infliximab for children with VEO-IBD. Better response with less infusion reaction was observed in children with NUC-PD and NUC-NPD vs that noted in children with UCT.